Immuron Limited Projects Record-Breaking Sales, On Track to Surpass A$7 Million This Financial Year

Reuters

2025/05/30

Immuron Limited Projects Record-Breaking Sales, On Track to Surpass A$7 Million This Financial Year

Immuron Limited, an Australian-based biopharmaceutical company, has announced a positive financial outlook for the current year, projecting sales to exceed A$7 million. This marks a significant increase from the A$4.9 million achieved in the previous year. The company attributes this growth to record sales up to the end of March, continuing momentum through the Easter and ANZAC holiday periods, and the spring and summer break in North America. Immuron's Chief Executive Officer, Steven Lydeamore, highlighted that the company is on track to surpass these sales figures, underscoring a momentous rise in revenue. Additionally, Immuron's clinical product, IMM-124E (Travelan®), is anticipated to generate US$102 million in yearly revenue in the United States, based on Lumanity's opportunity assessment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuron Limited published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9460623-en) on May 30, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2539223305"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2539223305\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2539223305?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-30 18:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2539223305","market":"us","top_or_hot":-1,"title":"Immuron Limited Projects Record-Breaking Sales, On Track to Surpass A$7 Million This Financial Year","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Immuron Limited Projects Record-Breaking Sales, On Track to Surpass A$7 Million This Financial Year\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Immuron Limited, an Australian-based biopharmaceutical company, has announced a positive financial outlook for the current year, projecting sales to exceed A$7 million. This marks a significant increase from the A$4.9 million achieved in the previous year. The company attributes this growth to record sales up to the end of March, continuing momentum through the Easter and ANZAC holiday periods, and the spring and summer break in North America. Immuron's Chief Executive Officer, Steven Lydeamore, highlighted that the company is on track to surpass these sales figures, underscoring a momentous rise in revenue. Additionally, Immuron's clinical product, IMM-124E (Travelan®), is anticipated to generate US$102 million in yearly revenue in the United States, based on Lumanity's opportunity assessment.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuron Limited published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9460623-en) on May 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Immuron Limited Projects Record-Breaking Sales, On Track to Surpass A$7 Million This Financial Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmuron Limited Projects Record-Breaking Sales, On Track to Surpass A$7 Million This Financial Year\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-05-30 18:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Immuron Limited Projects Record-Breaking Sales, On Track to Surpass A$7 Million This Financial Year\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Immuron Limited, an Australian-based biopharmaceutical company, has announced a positive financial outlook for the current year, projecting sales to exceed A$7 million. This marks a significant increase from the A$4.9 million achieved in the previous year. The company attributes this growth to record sales up to the end of March, continuing momentum through the Easter and ANZAC holiday periods, and the spring and summer break in North America. Immuron's Chief Executive Officer, Steven Lydeamore, highlighted that the company is on track to surpass these sales figures, underscoring a momentous rise in revenue. Additionally, Immuron's clinical product, IMM-124E (Travelan®), is anticipated to generate US$102 million in yearly revenue in the United States, based on Lumanity's opportunity assessment.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuron Limited published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9460623-en) on May 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IMC.AU","symbol_name":"IMMURON LTD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nNDL1y3bbG:1","article_id":"2539223305","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2539223305","pubTimestamp":1748599216,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Immuron Limited, an Australian-based biopharmaceutical company, has announced a positive financial outlook for the current year, projecting sales to exceed A$7 million. This marks a significant increase from the A$4.9 million achieved in the previous year. The company attributes this growth to record sales up to the end of March, continuing momentum through the Easter and ANZAC holiday periods, and the spring and summer break in North America. Immuron's Chief Executive Officer, Steven Lydeamore, highlighted that the company is on track to surpass these sales figures, underscoring a momentous rise in revenue. Additionally, Immuron's clinical product, IMM-124E , is anticipated to generate US$102 million in yearly revenue in the United States, based on Lumanity's opportunity assessment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for info","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"IMC.AU":"IMMURON LTD","NDAQ":"纳斯达克OMX交易所"},"translate_title":"Immuron Limited预计本财年销售额将破纪录，有望超过700万澳元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMC.AU":0.9,"NDAQ":0.9},"content_text":"Immuron Limited Projects Record-Breaking Sales, On Track to Surpass A$7 Million This Financial Year\n    \n\n        Immuron Limited, an Australian-based biopharmaceutical company, has announced a positive financial outlook for the current year, projecting sales to exceed A$7 million. This marks a significant increase from the A$4.9 million achieved in the previous year. The company attributes this growth to record sales up to the end of March, continuing momentum through the Easter and ANZAC holiday periods, and the spring and summer break in North America. Immuron's Chief Executive Officer, Steven Lydeamore, highlighted that the company is on track to surpass these sales figures, underscoring a momentous rise in revenue. Additionally, Immuron's clinical product, IMM-124E (Travelan®), is anticipated to generate US$102 million in yearly revenue in the United States, based on Lumanity's opportunity assessment.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuron Limited published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9460623-en) on May 30, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}